IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v37y2019i2d10.1007_s40273-018-0733-3.html
   My bibliography  Save this article

Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

Author

Listed:
  • Andrea Marcellusi

    () (University of Rome “Tor Vergata”
    Kingston University London)

  • Raffaella Viti

    (University of Rome “Tor Vergata”)

  • Loreta A. Kondili

    (Istituto Superiore di Sanità)

  • Stefano Rosato

    (Istituto Superiore di Sanità)

  • Stefano Vella

    (Istituto Superiore di Sanità)

  • Francesco Saverio Mennini

    (University of Rome “Tor Vergata”
    Kingston University London)

Abstract

Objective We estimated the cost consequence of Italian National Health System (NHS) investment in direct-acting antiviral (DAA) therapy according to hepatitis C virus (HCV) treatment access policies in Italy. Methods A multistate, 20-year time horizon Markov model of HCV liver disease progression was developed. Fibrosis stage, age and genotype distributions were derived from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER) cohort. The treatment efficacy, disease progression probabilities and direct costs in each health state were obtained from the literature. The break-even point in time (BPT) was defined as the period of time required for the cumulative costs saved to recover the Italian NHS investment in DAA treatment. Three different PITER enrolment periods, which covered the full DAA access evolution in Italy, were considered. Results The disease stages of 2657 patients who consecutively underwent DAA therapy from January 2015 to December 2017 at 30 PITER clinical centres were standardized for 1000 patients. The investment in DAAs was considered to equal €25 million, €15 million, and €9 million in 2015, 2016, and 2017, respectively. For patients treated in 2015, the BPT was not achieved, because of the disease severity of the treated patients and high DAA prices. For 2016 and 2017, the estimated BPTs were 6.6 and 6.2 years, respectively. The total cost savings after 20 years were €50.13 and €55.50 million for 1000 patients treated in 2016 and 2017, respectively. Conclusions This study may be a useful tool for public decision makers to understand how HCV clinical and epidemiological profiles influence the economic burden of HCV.

Suggested Citation

  • Andrea Marcellusi & Raffaella Viti & Loreta A. Kondili & Stefano Rosato & Stefano Vella & Francesco Saverio Mennini, 2019. "Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data," PharmacoEconomics, Springer, vol. 37(2), pages 255-266, February.
  • Handle: RePEc:spr:pharme:v:37:y:2019:i:2:d:10.1007_s40273-018-0733-3
    DOI: 10.1007/s40273-018-0733-3
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40273-018-0733-3
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Matteo Ruggeri & Federica Romano & Michele Basile & Silvia Coretti & Francesca Romana Rolli & Carlo Drago & Americo Cicchetti, 2018. "Cost-Effectiveness Analysis of Early Treatment of Chronic HCV with Sofosbuvir/Velpatasvir in Italy," Applied Health Economics and Health Policy, Springer, vol. 16(5), pages 711-722, October.
    2. Andrea Marcellusi & Raffaella Viti & Francesco Damele & Calogero Cammà & Gloria Taliani & Francesco Saverio Mennini, 2016. "Early treatment in HCV: is it a cost-effective option from the Italian perspective?," CEIS Research Paper 370, Tor Vergata University, CEIS, revised 23 Mar 2016.
    Full references (including those not matched with items on IDEAS)

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:37:y:2019:i:2:d:10.1007_s40273-018-0733-3. See general information about how to correct material in RePEc.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Sonal Shukla) or (Springer Nature Abstracting and Indexing). General contact details of provider: http://www.springer.com .

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service hosted by the Research Division of the Federal Reserve Bank of St. Louis . RePEc uses bibliographic data supplied by the respective publishers.